Immunostaining of PD-1/PD-Ls in liver tissues of patients with hepatitis and hepatocellular carcinoma

Table 5 Programmed death 1/programmed death ligands expression in liver tissues of patients with hepatocellular carcinoma (mean ± SD)

	n	PD-1	P	PD-L1	P	PD-L2	P
Age (yr)
< 49.3	21	6.45 ± 4.510	0.397	4.56 ± 4.304	0.779	4.73 ± 3.524	0.202
≥ 49.3	5	4.90 ± 3.872		4.00 ± 3.625		2.80 ± 3.120
Gender
Male	21	5.60 ± 4.154	0.844	4.45 ± 4.390	0.826	3.67 ± 3.619	0.769
Female	5	6.00 ± 4.147		4.00 ± 3.098		4.17 ± 3.061
Stage
I	5	4.75 ± 2.500	0.252	7.50 ± 2.121	0.0181	2.75 ± 1.893	0.624
IIa	6	7.00 ± 5.612		1.75 ± 1.500		2.60 ± 2.302
IIb	5	1.67 ± 1.528		3.00 ± 0.001		1.33 ± 1.528
Grade
I, II	12	5.78 ± 3.632	0.958	6.80 ± 5.495	0.153	4.00 ± 3.775	0.736
III, IV	10	5.67 ± 4.975		2.44 ± 1.878		3.44 ± 3.046
Etiology
HBV	21	5.60 ± 4.154	0.844	4.69 ± 4.231	0.464	3.73 ± 3.615	0.876
Unknown	5	6.00 ± 4.147		3.00 ± 2.449		4.00 ± 3.098

¹The significance among different stages is mainly the difference between stage I and Stage II (including IIa and IIb) according to the SNK analysis. PD: Programmed death; PD-L: Programmed death ligand; HBV: Hepatitis B virus.